Market Overview

The theranostics market was valued at USD 2.36 billion in 2025 and is projected to grow from USD 2.72 billion in 2026 to USD 8.67 billion by 2034, at a CAGR of 15.5% from 2026 to 2034, according to Polaris Market Research. The report describes theranostics as the integration of therapeutic and diagnostic approaches to provide personalized treatments, combining diagnostic tests such as imaging and biomarker assays with targeted therapies to optimize patient outcomes. North America was the largest market in 2025.

How Theranostics Differs from Traditional Treatment

Polaris contrasts theranostics with traditional approaches on several dimensions. Theranostics is personalized and targeted based on patient-specific biomarkers, integrates diagnostics and therapeutics into a single approach, and supports real-time, evidence-based treatment adjustments. Traditional approaches typically apply generalized protocols, conduct diagnosis and treatment separately, and may produce variable effectiveness among patients. The report adds that theranostics helps reduce unnecessary exposure to ineffective therapies.

Personalized Medicine Is the Core Growth Driver

Continued advancements in personalized medicine are a key driver of the theranostics market. The shift toward precision healthcare, which tailors treatment to an individual's genetic makeup, lifestyle, and other factors, has increased demand for targeted therapies and diagnostics. Genomic and molecular diagnostic tools enable more accurate identification of disease biomarkers, and biomarker assays play a central role in guiding therapeutic strategies, particularly in oncology. The rising adoption of molecular diagnostics allows detection and monitoring of disease markers at the molecular level, which is critical for early diagnosis and targeted treatment.

Artificial intelligence and data analytics are also improving diagnostic accuracy, treatment planning, and personalized care delivery, and advanced analytics support optimized radiopharmaceutical dosing and real-time disease monitoring, leading to faster clinical decisions. Polaris notes that targeted drug delivery systems are contributing to growth, and that oncology is where theranostics has shown promise in improving treatment efficacy and reducing side effects. Companies are expanding portfolios through research and development, collaborations, and acquisitions, with investments in biomarker discovery and targeted therapies and a growing emphasis on geographic expansion in emerging markets.

Companion Diagnostics and Molecular Imaging

Technological innovation in companion diagnostics is described as significantly influencing market opportunities. These tests are designed to predict the effectiveness of a specific therapeutic intervention, ensuring that the right patient receives the right treatment, and they increasingly use genetic, genomic, or proteomic markers. The approval of several targeted therapies, such as those used for breast or lung cancer, has been closely linked with companion diagnostics.

Polaris also highlights growing use of molecular imaging, including PET and SPECT, together with advanced biomarkers for precise diagnosis and treatment monitoring. In March 2026, OncoLux Inc. and Mayo Clinic entered a know-how agreement to advance optical theranostics in robotic bronchoscopy.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/global-theranostics-market 

Radiotheranostics and Oncology Leadership

Radiotheranostics is identified as a key trend, reflecting increasing use of radiopharmaceuticals in cancer treatment, particularly for prostate cancer and neuroendocrine tumors. In April 2025, Telix entered a distribution agreement with Cardinal Health for Gozellix, integrating ARTMS QUANTM systems across Cardinal's network to enable localized gallium-68 production.

Oncology led the application segments with a 62.7% share in 2025, propelled by the rising prevalence of cancer globally and growing adoption of targeted therapies. Neurology, while smaller, is registering the fastest growth at a CAGR of 15.3%, driven by neurodegenerative diseases such as Alzheimer's and Parkinson's and by diagnostic tools for early detection.

Regionally, North America held a 46.2% revenue share in 2025, supported by advanced healthcare infrastructure and high adoption of precision medicine, while Asia Pacific is expected to register the highest CAGR of 17.0% during the forecast period.

Key Players

• Abbott Laboratories
• Advanced Accelerator Applications
• Astellas Pharma Inc.
• Bayer AG
• Cardinal Health, Inc.
• Curium Pharma
• Hoffmann-La Roche AG
• GE HealthCare Technologies Inc.
• Illumina, Inc.
• Lantheus Holdings, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.

Conclusion

The theranostics market reflects a broader shift toward care that is matched to the individual patient. Personalized medicine provides the strategic rationale, companion diagnostics and molecular imaging supply the clinical tools, and radiotheranostics is opening new treatment options in cancer. With oncology leading and neurology growing quickly, B2B stakeholders should look closely at partnerships that connect diagnostic and therapeutic capabilities. The full Polaris Market Research report offers additional detail on segments, regions, and competitive activity.

More Trending Latest Reports By Polaris Market Research:

Construction Chemicals Market

Face Mask Market

Bamboos Market

Plastic Waste Management Market

Endoscopy Devices Market

Outdoor Power Equipment Market

Outdoor Power Equipment Market

Bamboos Market

Nanorobotics Market